◼ Archived
Business
🔮 fades ✗
Compass says depression drug has long-lasting benefits
Compass Pathways reports long-lasting benefits from its psilocybin depression treatment following a second Phase 3 trial.
3 trends tracked about this subject — the full history, oldest to newest below.
Compass Pathways reports long-lasting benefits from its psilocybin depression treatment following a second Phase 3 trial.
An 80-year-old woman with Alzheimer's has regained speech and mobility after taking psilocybin.
A controversial case report on psilocybin's effects on an Alzheimer's patient has sparked global interest.